GLOBUS MEDICAL INC (GMED): Results of Operations and Financial Condition
GLOBUS MEDICAL INC (GMED) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Globus Medical Reports Second Quarter 2026 Results AUDUBON, PA., August 6, 2026: Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced its financial results for the second quarter ended June 30, 2026. Second Quarter 2026: •
How this was made
The 30-second read
Why it matters
The key tradable inputs are the raised full-year non-GAAP EPS range and the Q2 non-GAAP EPS surge, supported by commentary on adjusted gross margin expansion and operating leverage.
Market read
GMED’s guidance update (non-GAAP EPS raised) and Q2 non-GAAP profitability improvement are fresh catalysts that can drive near-term positioning and options implied moves.
What to watch
Traders may discount non-GAAP strength if they expect normalization of adjusted items or if revenue growth is concentrated in specific product lines (US Spine and International Spine) rather than broad-based durability.
Globus Medical reported 5.9% worldwide net-sales growth and raised full-year non-GAAP fully diluted EPS guidance.
Worldwide net sales increased 5.9%, non-GAAP diluted EPS increased 55.8%, and the Company raised non-GAAP fully diluted EPS guidance while reaffirming revenue guidance. GAAP net income and GAAP diluted EPS declined because the prior-year quarter included a $110.5 million bargain purchase gain related to the Nevro acquisition.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| Worldwide net salesGAAP | $789.6 million | – | 5.9% |
| Worldwide net sales growth, constant currencyother | 5.6% | – | 5.6% |
| U.S. net sales growthGAAP | 3.0% | – | 3.0% |
| International net sales growth, as reportedGAAP | 18.0% | – | 18.0% |
| International net sales growth, constant currencyother | 16.2% | – | 16.2% |
| GAAP net incomeGAAP | $151.6 million | – | (25.3%) |
| GAAP diluted EPSGAAP | $1.10 | – | (26.2%) |
| Non-GAAP diluted EPSnon-GAAP | $1.34 | – | 55.8% |
| Adjusted gross margin expansionnon-GAAP | 200 basis points | – | 200 basis points |
| Base business revenue growth excluding Nevroother | 9% | – | – |
| US Spine growthother | 7% | – | – |
| International Spine growth, as reportedother | 14% | – | – |
| International Spine growth, constant currencyother | 12% | – | – |
Full-year 2026 outlook
- Revenue$3.18 billion to $3.22 billion
- NoteNon-GAAP fully diluted EPS: $4.95 to $5.05
- NotePrevious non-GAAP fully diluted EPS range: $4.70 to $4.80
What drove it
- Share gains across a majority of underlying businesses.
- US Spine grew 7%.
- International Spine grew 14% as-reported and 12% on a constant currency basis.
- Adjusted gross margin expanded 200 basis points compared to the second quarter of the prior year.
- The Company cited margin expansion, operating leverage, and synergy realization.
Concerns
- GAAP net income decreased 25.3% over the same period in the prior year.
- GAAP diluted EPS decreased 26.2%, primarily driven by the $110.5 million bargain purchase gain recognized in the prior-year quarter related to the Nevro acquisition.
- U.S. net sales increased 3.0%, below international net-sales growth of 18.0% as reported.
What to watch
- Delivery against reaffirmed full-year 2026 revenue guidance of $3.18 billion to $3.22 billion.
- Delivery against updated full-year 2026 non-GAAP fully diluted EPS guidance of $4.95 to $5.05.
- Whether adjusted gross margin expansion, operating leverage, and synergy realization continue.
- U.S. net-sales growth and the stated US Spine share gains.
- The contribution from Nevro, given management's cited 9% base-business revenue growth excluding Nevro.
Analysis
Globus Medical reported worldwide net sales of $789.6 million, up 5.9% as reported and 5.6% on a constant currency basis. The release described 9% base-business revenue growth excluding Nevro. Geographic performance was uneven: U.S. net sales increased 3.0%, while international net sales increased 18.0% as reported and 16.2% on a constant currency basis.
Management identified share gains across a majority of underlying businesses as the principal demand driver. US Spine grew 7%, and International Spine grew 14% as reported and 12% on a constant currency basis. The Company characterized US Spine as its fifth consecutive quarter of above-market revenue growth and cited continued strength across its product portfolio.
Profitability diverged sharply between GAAP and non-GAAP results. GAAP net income was $151.6 million, down 25.3%, while GAAP diluted EPS was $1.10, down 26.2% from $1.49. The release attributed the GAAP declines primarily to a $110.5 million bargain purchase gain tied to the Nevro acquisition that was recognized in the prior-year quarter. Non-GAAP diluted EPS was $1.34, up 55.8% from $0.86, alongside 200 basis points of adjusted gross margin expansion.
The Company reaffirmed full-year 2026 revenue guidance of $3.18 billion to $3.22 billion and raised non-GAAP fully diluted EPS guidance to $4.95 to $5.05 from $4.70 to $4.80. Management linked the earnings outlook to margin expansion, operating leverage, and synergy realization. The primary reported items to monitor are the pace of U.S. net-sales growth, continuation of international and spine growth, and whether the stated margin and synergy benefits support the higher non-GAAP EPS range.
Management, verbatim
Momentum continued into the second quarter with 6% overall revenue growth, or 9% growth excluding Nevro, driven by share gains across a majority of our underlying businesses, most notably US Spine, growing 7% and International Spine, growing 14% as-reported and 12% on a constant currency basis.
Keith Pfeil, President and Chief Executive Officer
US Spine, again, led the way in growth for the organization, marking our fifth straight quarter of above-market revenue growth, with continued strength across our entire product portfolio.
Kyle Kline, Chief Financial Officer
The strength of our second-quarter performance reflects disciplined execution across the business, including margin expansion, operating leverage, and synergy realization, which position us to deliver sustained earnings growth, and enhanced shareholder returns throughout the year.
Kyle Kline, Chief Financial Officer
Not in the filing
stated, not guessed- Prior-year worldwide net sales dollars.
- U.S. net sales dollars and prior-year U.S. net sales dollars.
- International net sales dollars and prior-year international net sales dollars.
- Revenue dollars for US Spine and International Spine.
- GAAP gross profit and GAAP gross margin.
- Non-GAAP gross profit and non-GAAP gross margin value.
- GAAP operating income or loss.
- Non-GAAP operating income or loss.
- Non-GAAP net income.
- Non-GAAP Adjusted EBITDA.
- Operating cash flow.
- Free cash flow.
- Capital expenditures.
- Cash and cash equivalents.
- Debt and other balance-sheet data.
- Share repurchases.
- Dividends.
- Prior-quarter comparisons for reported metrics.
- Full-year 2026 gross-margin, operating-expense, and tax-rate guidance.
- Previous-release outlook needed for formal actual-versus-prior-guidance comparisons.
AlphaAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
This is an SEC 8-K with Exhibit 99.1 reporting Globus Medical’s Q2 2026 financial results and full-year 2026 guidance update, plus conference call details.
Ticker impact
Globus Medical reported Q2 2026 results and updated full-year guidance, including raising non-GAAP EPS to $4.95-$5.05.
Likely positive bias for the next session as traders weigh raised non-GAAP EPS guidance versus GAAP EPS distortion from the prior-year Nevro bargain purchase gain.
The filing provides fresh, decision-relevant numbers: Q2 non-GAAP diluted EPS up 55.8% and full-year non-GAAP EPS range raised to $4.95-$5.05, alongside revenue growth and margin expansion commentary.
Market effects
Musculoskeletal/spine medtech peers may see read-across on demand and margin trajectory if GMED’s growth and adjusted profitability are sustained.
International revenue growth (up 18% as-reported) highlights continued ex-US momentum that could influence regional medtech sentiment.
Limited direct global macro linkage, but guidance revisions can affect broader risk appetite in medtech earnings season.
Counterpoint
GAAP EPS fell 26.2% due to the prior-year Nevro bargain purchase gain, so headline EPS comparisons may overstate underlying operating momentum.
Key entities
- companyGlobus Medical, Inc.
Subject of the filing, reporting Q2 2026 results and updating full-year 2026 guidance.
- executiveKeith Pfeil
CEO quoted on revenue growth drivers and the company’s ecosystem strategy.
- executiveKyle Kline
CFO quoted on margin expansion, operating leverage, and synergy realization.
